Purpose Histone deacetylase inhibitors (HDACis) have been shown to overcome resistance
to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) linked to …

Purpose Erlotinib prolonged survival of unselected patients with advanced non–small-cell
lung cancer (NSCLC) who were not eligible for further chemotherapy, and two phase II …

Background: Erlotinib is a standard of treatment for metastatic non-small-cell lung cancer
after failure of initial therapy. Patient selection based on clinical factors is under discussion …

Background: Second-line chemotherapy for advanced non-small cell lung cancer (NSCLC)
improves survival modestly but new strategies are needed. This trial was designed to …

In the US and Europe, the current options for the second-and third-line treatment of
advanced non-small cell lung cancer (NSCLC) are cytotoxic drugs and targeted agents …

Introduction: Bevacizumab is approved in combination with chemotherapy as first-line
treatment for non-small cell lung cancer (NSCLC). Preclinical data suggest that enzastaurin …

Purpose In the phase III PARAMOUNT trial, pemetrexed continuation maintenance therapy
reduced the risk of disease progression versus placebo (hazard ratio [HR], 0.62; 95% CI …

Introduction: This phase 2 study was conducted to determine the efficacy and safety of
erlotinib alone and with bortezomib in patients with non-small cell lung cancer (NSCLC) …

Pemetrexed is a newer antifolate drug that has been approved as first-line treatment for
patients with advanced non-squamous, non-small cell lung cancer (NSCLC) in combination …

Objectives Retrospective subgroup analysis in JMDB study indicates that the between-arm
differences in overall survival (OS) in the East Asian subgroup were consistent with those …